Antibody-dependent cellular cytotoxicity (ADCC) is one of the possible mechanisms of action of the chimeric CD20 monoclonal antibody IDEC-C2B8 (rituximab). As granulocyte-colony stimulating factor (G-CSF) greatly enhances the cytotoxicity of neutrophils in ADCC, the efficacy of rituximab might be enhanced by the addition of G-CSF. In a phase I/II clinical trial, we investigated the safety and efficacy of the combination of rituximab and G-CSF (5 lg/kg/day, administered for 3 days, starting 2 days before each infusion) in 26 relapsed low-grade lymphoma patients. Adverse events occurred in 25/26 patients and mainly consisted of (grade I/II) fever (29%) and allergic reactions (19%). In phases I and II (375 mg/m 2 rituximab+G-CSF), 19 patients were evaluable for efficacy. The response rate was 42% (8/19; 95% CI 20-67%), with 16% (3/19) complete remissions and 26% (5/19) partial remissions. The median duration of response was 18 months, the median time to progression was 24 months. We conclude that the combination of rituximab and G-CSF is well tolerated. Although the overall response rate seems comparable to that reported for rituximab monotherapy, remission duration in this pilot phase II study is remarkably long. Randomized comparison with rituximab monotherapy should substantiate this promising finding.
Introduction
Despite the development of new (chemo-)therapy regimens, the median survival time in low-grade non-Hodgkin's lymphoma (NHL) has not changed over the past decades and cure remains elusive. Thus, the need for new treatment modalities has not abated. Chimeric anti-CD20 mAbs (IDEC-C2B8, rituximab) have been shown to be a promising new option. [1] [2] [3] [4] It has been demonstrated in B-cell lines in vitro that rituximab can induce complement-dependent cytotoxicity (CDC) [5] [6] [7] and antibodydependent cellular cytotoxicity (ADCC), the latter with mononuclear cells as effector cells. 5 Furthermore, ligation of CD20 inhibits B-cell proliferation 8 and it has been described that CD20 mAbs can induce apoptosis in B-cell lines, which is enhanced after crosslinking. [9] [10] [11] The importance of FcgR-mediated mechanisms for in vivo cytotoxicity of monoclonal antibodies, including rituximab, was clearly demonstrated in animal studies. 12 More recently, an association was found between the FCGR3A-158V genotype and a better response to rituximab treatment, suggesting the involvement of FcgRIIIa NK in the antitumor mechanism of rituximab. 13, 29 Hence, although the exact mechanism of action of the CD20 mAb in vivo has not been established yet, these studies support an important role for Fcg-receptor dependent mechanisms in the efficacy of rituximab treatment.
In a clinical trial in 166 relapsed low-grade NHL-patients treated with 375 mg/m 2 rituximab weekly 4 Â , the overall response rate was 48% and the median time to progression was 13 months. 2 Thus, although clinical results with rituximab as single agent therapy are encouraging, they might still be improved. Therefore, several strategies to improve the clinical activity of rituximab are currently being investigated [14] [15] [16] [17] Kimby et al, Blood 2000; 96: 2479 (abstract)).
A possibility to improve the efficacy of unconjugated mAbs might be to enhance the efficacy of the effector cells involved in ADCC, one of the possible antitumor mechanisms of monoclonal antibodies. Granulocyte-colony-stimulating factor (G-CSF) greatly enhances the cytotoxic capacity of neutrophils in ADCC assays. [18] [19] [20] It has been demonstrated, in vitro as well as in vivo in healthy volunteers, that G-CSF induces the expression of Fcg-receptor type I (FcgRI) on neutrophils via an effect on myeloid precursor cells. 19, 21 This FcgRI appeared to be the main FcgR involved in neutrophil-mediated ADCC assays. 18, 19 Furthermore, G-CSF administration leads to a large increase in the number of circulating (FcgRI-positive) neutrophils. Therefore, adding G-CSF to rituximab therapy could theoretically enhance the efficacy of rituximab by exploiting the mechanism of ADCC.
We performed a phase I/II clinical trial to evaluate the safety (phase I) and efficacy (phase II) of the combination of rituximab and G-CSF. We hereby present the final data on safety and efficacy of this combination.
Materials and methods

Study design
This was an open label, single arm phase I/II study. Patients were enrolled and treated in the Academic Medical Center and the Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands. The study was approved by the ethics committee at each center and performed according to the guidelines of the Declaration of Helsinki. Each patient received a total of 4 weekly intravenous (i.v.) doses of rituximab (IDEC-C2B8, Rituxan s , Mabthera s , IDEC Pharmaceuticals, San Diego, CA, USA) in combination with a standard dose of G-CSF (filgrastim, Neupogen; Amgen, Thousand Oakes, CA, USA; 5 mg/kg/day subcutaneously) administered for 3 days, starting 2 days before each infusion of rituximab ( Figure 1) .
The phase I part of the study consisted of a dose escalation of rituximab, in combination with the standard dose of G-CSF. Cohorts of three patients were entered at each dose level of rituximab (125, 250 or 375 mg/m 2 rituximab weekly Â 4). Dose escalation was allowed only in the absence of serious toxicity, defined as grade 3 renal toxicity or any grade 4 drug-related toxicity according to the National Cancer Institute's Adult's Toxicity Criteria. Rituximab was administered according to the guidelines described in the investigational drug brochure. 22 During the phase I, no premedication was given. After evaluation of the phase I, the dose of rituximab for the phase II study was established at 375 mg/m 2 . In order to prevent the 'allergic reactions' and fever, which were observed frequently during the phase I (see 'Results'), it was decided to give premedication during the phase II, consisting of clemastine (2 mg i.v.) and paracetamol (1000 mg). Corticosteroids were never given as premedication. Since in phase I side effects were almost exclusively observed during the first infusion, premedication was only given before the first infusion.
Patients
Adults (418 years) were eligible if they had measurable relapse or progression of histologically confirmed CD20-positive B-cell lymphoma. In the phase I part, patients with low and intermediate grade NHL were included (working formulation (WF) A-D). In the phase II part, only low-grade NHL patients were included (WF A-C). All patients had to meet the following inclusion criteria: expected survival of 43 months; prestudy performance status of 0-2 according to the World Health Organization (WHO) scale; relapse or progression after at least one and no more than three prior systemic therapies; seronegative for human immunodeficiency virus (HIV) and hepatitis-B surface antigen (HBsAg); serum IgG4600 mg/dl; hemoglobin 
Clinical parameters
Monitoring of safety was performed throughout the study and included medical history, vital signs, analysis of renal, hepatic and hematologic parameters and analysis of Ig levels. Toxicity was evaluated according to the National Cancer Institute's Adult's Toxicity Criteria.
Response criteria were as follows: a complete remission (CR) required complete disappearance of all clinically detectable disease, including bone marrow infiltration, for at least 28 days; partial remission (PR) was defined as a X50% decrease in overall tumor size without any evidence of disease progression for at least 28 days; stable disease (SD) was defined as p50% decrease or p25% increase in overall tumor size, without any evidence of progression; progressive disease (PD) was defined as X25% increase in overall tumor size, or X50% increase in any single lesion, or the appearance of new lesions. Follow-up by physical examination, lab, CT-scans and bone marrow aspiration was at 1, 2 and 3 months after last infusion of rituximab. After this period, the above-mentioned investigations were performed when clinically indicated.
Duration of response was measured from initial observation of response until the last date that the measurements satisfied the criteria of the response. Time to progression was measured from first study treatment until the first date when PD was documented.
Immunophenotypical analysis
Mabs against CD11b (CLB-mon-gran/1, B2), CD13 (CLB-mongran/2), CD16 (CLB-FcRgran/1, 5D2), CD45 (CLB-T200/1, 15D9), CD64 (10.1), CD66b (CLB-B13.9) and the irrelevant control antibodies IgG1 and IgG2a were from the Central Laboratory of the Netherlands Red Cross Blood Transfusion Service (CLB, Amsterdam, The Netherlands). FITC-conjugated rabbit anti-mouse-Ig (F(ab 0 ) 2 fragments) and Kappa and Lambda mAbs were from Dako (Glostrup, Denmark). Mean fluorescence intensity (MFI) was measured by flow cytometry (FACS-scan, Becton Dickinson, San Jose, CA, USA) and data were always corrected for the MFI in the presence of irrelevant control antibody.
Elastase/lactoferrin
Plasma levels of elastase-a 1 -antitrypsin complexes (further referred to as elastase) and lactoferrin were measured with radioimmunoassays (RIA) as described before. 23 The levels are expressed as ng/ml using preformed complexes and purified lactoferrin as standards, respectively. Levels of elastase and lactoferrin in healthy individuals are below 100 and 400 ng/ml, respectively. 23 
Statistics
Statistical analysis was performed using the SPSS statistical package (SPSS for Windows, version 8.0). Data are expressed as means7s.e.m., unless indicated otherwise. Serum concentrations were compared using the Wilcoxon's signed ranks test. Correlations were assessed using Pearsoń s correlation coefficient. Differences in response rates between the groups were tested for statistical significance using Fisher's exact test (two-G-CSF rituximab week I I I I V III Figure 1 Treatment schedule. Patients were treated with the combination of rituximab and G-CSF. Rituximab was given weekly for 4 weeks. G-CSF (5 mg/kg/day) was administered for 3 days, starting 2 days before each infusion of rituximab (ie, the third injection of G-CSF was administered several hours before rituximab infusion). Follow-up was at 1, 2 and 3 months. sided). The duration of response and time to progression were assessed using the method of Kaplan and Meier. A P-value p0.05 was considered significant.
Results
Patient characteristics
Nine patients were treated in the phase I part of the study, three patients at each consecutive dose level. Patient characteristics are listed in Table 1 . The median age was 53 years (range 32-59 years) and the histologic subtype was low grade NHL in seven patients and intermediate grade NHL in two patients. In the phase II, 17 patients have been treated. The median age was 53 years (range 27-75 years) and all patients had a low-grade NHL ( Table 1 ). The median number of prior systemic therapies was 2, and regimens included CVP (n ¼ 19 patients), CHOP (n ¼ 8), chlorambucil (n ¼ 5) and fludarabin (n ¼ 6). One patient had undergone high-dose chemotherapy with stem cell rescue 5 months before study entry.
Toxicity
All, but one, patients received the 12 injections of G-CSF according to the study protocol. Administration of G-CSF did not induce significant toxicity. However, there were patients who experienced mild bone pain or flu-like symptoms. In those patients it was advised to take paracetamol (1000 mg) before G-CSF administration. One patient had experienced grade II side effects (bone pain) during the first cycle of G-CSF. At her request, she did not receive G-CSF preceding the subsequent rituximab infusions. The nine patients included in the phase I all completed the four cycles of rituximab treatment and were evaluable for safety. No premedication was given.
Adverse events are summarized in Table 2 . Toxicity during rituximab treatment was experienced by eight (out of nine) patients and consisted mainly of infusion-related adverse events (total number of adverse events ¼ 30). The most frequent adverse events were fever and 'allergic reactions' consisting of rhinitis, sneezing, itching of the oropharynx and a sensation of swelling of the throat. There was no apparent relation between the dose of rituximab and the amount or severity of the adverse events (see Table 1 ). The infusion-related adverse events typically occurred 1-2 h after onset of the infusion. Most events were classified as mild to moderate (toxicity grades 1-2) and occurred during the first infusion; only few patients experienced adverse events during subsequent infusions. One patient developed a viral stomatitis (2 weeks after completion of rituximab therapy), which was complicated by a bacterial superinfection. This infection resolved upon treatment with acyclovir and antibiotics. Although no serious infusion-related toxicity was observed during the phase I, it was decided to treat patients participating in the phase II study prophylactically with clemastine (2 mg i.v.) and paracetamol (1000 mg) in order to attenuate the allergic reactions that were frequently observed during the phase I study.
Infusion-related side effects observed in the phase II were comparable to those documented in phase I. However, the allergic reactions as described in the phase I patients appeared to occur less frequently in these patients (nine/61 during phase II vs eight/30 during phase I) and were clinically less pronounced than during phase I. Only mild hematologic toxicity was observed (grades 1-2) and parameters usually recovered at follow-up. No renal or hepatic toxicity was observed (data not shown).
Neutrophil activation upon G-CSF-administration
Neutrophil activation upon G-CSF-administration was assessed (1) by analysis of phenotypic changes of neutrophils and (2) by Pain at tumor sites.
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measuring plasma levels of elastase and lactoferrin as markers for neutrophil degranulation. 24 Analysis of phenotypic changes of neutrophils upon G-CSF-administration: The rationale of adding G-CSF to the treatment with rituximab was to induce the expression of the FcgRI on the circulating neutrophils, while at the same time increasing their number. As shown in Figure 2 , directly prior to the start of the first rituximab infusion the number of neutrophils was strongly increased (from 470.4 Â 10 9 /l to 1972 Â 10 9 /l, Po0.001). Moreover, FcgRI expression on neutrophils rose from 2679 (MFI) at baseline to 6878 (P ¼ 0.001) after 3 days of G-CSF. At 3 days after treatment, the mean expression level of FcgRI on circulating neutrophils was still elevated. The increase in neutrophil count and induction of FcgRI-expression by G-CSF showed a comparable pattern during the first week and the fourth week of treatment (Figure 2) . CD11b (C3bi receptor), CD13 (aminopeptidase N), CD45 (membrane-associated tyrosine phosphatase) and CD66b (CEA/ like antigen, mainly localized in the specific granules) are antigens considered to be associated with neutrophil activation. Expression levels of these antigens were determined by flow cytometry, at different time points during the first and fourth week of treatment and all values were compared to baseline levels (week 1, time point À48 h, see legend of Figure 2 ). CD13, CD16 (FcgRIII) and CD11b decreased upon G-CSF administration (Figure 2b ). However, expression returned to normal at day 3 after rituximab treatment. There was no significant change in the mean expression of CD45 and CD66b (not shown).
Measurements of plasma levels of elastase and lactoferrin as markers for neutrophil degranulation: The concentration of elastase was 4977 ng/ml at baseline (t ¼ À48 h). After three injections of G-CSF, the concentration increased to 129720 ng/ml (t ¼ À1 h, just before rituximab infusion; P ¼ 0.018). After 3 days (t ¼ +72 h), levels had returned to normal (o100 ng/ml). The same pattern was observed during the fourth week of treatment (Figure 3a) . Lactoferrin levels rose from 179735 ng/ml at baseline to 3957112 ng/ml after three injections of G-CSF (t ¼ À1 h; not significant (NS)), which is just within normal limits. At 72 h after the third injection of G-CSF, lactoferrin levels further increased to 4327100 ng/ml (t ¼ +72 h, NS) (Figure 3b ). During the fourth week of treatment, lactoferrin levels were significantly increased when compared to baseline values (Po0.05 at all time points, Figure 3b) . In two control patients, treated with rituximab (375 mg/m 2 ) only, levels of elastase or lactoferrin did not change at these time points, indicating that the observed increases were due to G-CSF pretreatment.
Neutrophil activation upon rituximab infusion
To investigate whether neutrophils were additionally activated during infusion of rituximab, we assessed kinetics of plasma levels of elastase and lactoferrin during the first infusion of the antibody in five patients. At the start of the infusion, levels were already slightly increased due to G-CSF pretreatment (see previous paragraph). Upon infusion of rituximab, elastase rose from 165738 ng/ml to a maximum of 301736 ng/ml at 180 min; lactoferrin rose from 254736 ng/ml at baseline to a maximum of 6307172 at 90 min. At the end of the infusion, elastase and lactoferrin had almost returned to preinfusion values (Figure 3c ).
Response
In total, 20 patients have been treated with the highest dose of rituximab (375 mg/m 2 ) in combination with G-CSF, three in phase I and 17 in phase II part of the study. Since one patient did not receive all G-CSF injections, 19 patients were evaluable for response ( Table 3 ). The response rate was 42% (8/19) (95% CI 20-67%) (40% on intent-to-treat basis). In two patients, the CR could not be confirmed by bone marrow biopsy due to patient refusal. These patients both had bone marrow involvement prior to rituximab treatment, and are therefore considered to have a PR. The percentage of CRs was 16% (three/19), the percentage of PRs was 26% (five/19). The median duration of response was 18 months, the median time to progression was 24 months. At a median follow-up of 50 months, two patients are still in remission for 52+ and 56+ months (Table 4 ). In four (from eight) patients, the duration of response to rituximab treatment was considerably longer than the response to last systemic regimen (Table 4) . Although the sample size is rather small, factors that have previously been reported to influence the response to rituximab treatment were analyzed in our patient group as well. Patients that achieved a CR or PR to their last prior chemotherapy regimen (n ¼ 11) seemed to have a better response to rituximab therapy than patients who did not respond to last prior therapy (n ¼ 8) (response rate 63% (seven/11) vs 13% (one/eight) respectively, P ¼ 0.059). No correlations were found between response rate and number of prior regimens, bulky disease, bone marrow infiltration and extranodal lesions. In previous studies, WF A lymphoma was found to be correlated with a lower response to rituximab treatment, as compared to WF B and/or WF C lymphoma. 2, 25 Among the 19 evaluable patients in the present study, there were four with WF A lymphoma (three patients with immunocytoma (Kiel classification) and one with marginal zone lymphoma (Real classification)). These patients were all nonresponders.
Discussion
In the present study, we evaluated safety and efficacy of the combination of rituximab and G-CSF in relapsed low-grade NHL patients.
Side effects of G-CSF were mild and consisted mainly of bone pain and flu-like symptoms, which is in agreement with previous studies on G-CSF administration. 26 Side effects during rituximab infusion were mild (grades 1-2) and included mainly fever and 'allergic reactions', consisting of sneezing, rhinitis and itching of the oropharynx. Thus, the combination therapy of rituximab and G-CSF was well tolerated and toxicity appeared to be similar to that reported for rituximab monotherapy. 2, 27 The expression of FcgRI on neutrophils was significantly increased after three injections of G-CSF (ie just prior to rituximab infusion) (Figure 2) . Previously, the capacity of CD20 mAbs in mediating ADCC has been questioned. 20 We found however, that chimeric CD20 mAbs were capable of inducing ADCC in B cells with G-CSF-primed neutrophils as effector cells, whereas unstimulated neutrophils could not induce CD20-dependent ADCC. 28 Thus, as intended, G-CSF administration resulted in FcgRI-positive, cytotoxic neutrophils. Last systemic chemotherapy regimen.
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In this study, 19 patients were evaluable for efficacy. The response rate to the combination of rituximab and G-CSF was 42% (95% CI 20-67%), and comparable to the response rate achieved with rituximab monotherapy. 2, 25 Interestingly, the duration of responses was remarkably long. At a median followup of 50 months, two (from eight) responders were still in remission, for 52+ and 56+ months. The median time to progression was 24 months, which seems to be longer than described in previous studies on rituximab monotherapy. 2 Furthermore, in four from eight patients, remission duration was considerably longer than remission duration achieved on last previous systemic therapy. Thus, although the overall response rate was not increased, addition of G-CSF to rituximab may be beneficial by increasing response duration.
With 53% of the evaluable patients having received only one prior systemic regimen and no refractory patients, this patient group was slightly skewed. However, the number of prior systemic regimens did not seem to influence the response to the combination of rituximab and G-CSF. Still, since the number of patients treated in this study is rather small, more patients are needed to confirm our observations. In recent studies an association was found between the FCGR3A genotype and the response to rituximab treatment. 13, 29 This finding might indicate a role for the FcgRIIIa NK in the antitumor mechanisms of rituximab. Although in our study the influence of G-CSF on the expression of FcgRIIIa NK was not investigated, we did find a decrease in the expression of FcgRIIIb on neutrophils from all patients. Since we previously demonstrated that ADCC of G-CSF-stimulated neutrophils on B cells was mediated mainly by FcgRI, 28 we do not think that the decrease in FcgRIIIb expression on the neutrophils influenced the response to the combination of rituximab and G-CSF in this study.
In the present study, lymph node biopsies were taken 1 day after the last rituximab infusion in three patients. Although the lymphocytes were coated with rituximab, as was also observed in previous studies, 5, 30 only few neutrophils were observed (data not shown). Thus, at least at the described time point, neutrophils had not migrated to tumor sites in large numbers. In order to emigrate to lymphatic tissue or sites of inflammation, neutrophils need to be attracted (by chemoattractants, eg cytokines, histamine, C5a) and migratory capacity should be adequate. Although B cells in lymph nodes were coated with rituximab, the degree of inflammation induced by rituximab at tumor sites might have been insufficient to initiate neutrophil migration. Furthermore, compared to unstimulated neutrophils, in vivo G-CSF stimulated neutrophils show certain differences that may influence the migratory capacity in vivo. For example, the directed migration (chemotaxis) of in vivo G-CSF-stimulated neutrophils was found to be decreased. [31] [32] [33] Thus, insufficient migration might have hampered the beneficial effects of G-CSF. However, since only three biopsies were taken at one time point, we cannot draw definite conclusions as to this possibility.
Recently, results of a clinical trial evaluating the safety and efficacy of the combination of rituximab and interferon-a-2a (IFN-a) were published. 17 IFN-a has, among other effects on the immune system, the ability to stimulate NK cells in mediating ADCC. Thus, combining rituximab with G-CSF or IFN-a is at least in part a similar approach intended to increase the efficacy of rituximab.
The overall response rate of the combination of rituximab and IFN-a was 45% (ie similar to rituximab monotherapy), but response duration appeared to be longer than for rituximab monotherapy. However, side effects observed during treatment with rituximab and IFN-a were more severe, including grade 3 adverse events in 12 patients. The majority of the side effects were attributed to IFN-a. Hence, although the potential beneficial effects of IFN-a and G-CSF on the response duration of rituximab may be similar, the safety profile of the combination with G-CSF is clearly more favorable.
In conclusion, the combination of G-CSF and rituximab was safe and well tolerated in relapsed low-grade NHL patients. The response rate was comparable to that reported for rituximab monotherapy, however, remission duration in this small-sized phase II study was remarkably long. Randomized comparison with rituximab monotherapy should substantiate this promising finding.
